LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
WALTHAM, Mass., May 15, 2017 -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Morrison, M.D., will present at the 2017 UBS Global Healthcare Conference on May 22, 2017 at 11:30 am EDT at the Grand Hyatt New York.
A live webcast of the Company's presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Given its potential ability to block the function of immune suppressive cells in the tumor microenvironment, entinostat is also being evaluated in combination with approved PD-1 antagonists. Ongoing Phase 1b/2 clinical trials combine entinostat with KEYTRUDA® from Merck & Co., Inc. for non-small cell lung cancer and melanoma; with TECENTRIQ® from Genentech, Inc. for TNBC; and with BAVENCIOTM from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. Our second product candidate, SNDX-6352, is a monoclonal antibody that blocks the CSF-1 receptor and may also block the function of immune suppressive cells in the tumor microenvironment. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers.
Investor Contact Heather Savelle Argot Partners [email protected] Tel 617.340.6072 Media Contact Eliza Schleifstein Argot Partners [email protected] Tel 973.361.1546
